Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times the institutional ULN (unless elevated secondary to lymphomatous involvement of the liver, in which case the AST/ALT must be =< 5 times the institutional ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN
Participants must have total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times ULN.
Adequate liver function (total bilirubin ? 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN
Within 30 days prior to enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN
Alanine aminotransferase (ALT) < 5 times ULN
Serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ?2 times the upper limit of normal (ULN); ? 5 times ULN if there is liver or bone involvement.
Hepatic: Bilirubin ?1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) ? 3.0 times ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN
Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN
Aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or alanine aminotransferase (ALT) > 5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ?5 times ULN).
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 times the ULN; if liver metastases are present, then ? 5 times the ULN is allowed.
Alanine aminotransferase (ALT) greater than 2.0 times the ULN in the absence of known hepatic metastases
AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN (measured within 28 days of registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) if no hepatic metastasis =< 2.5 times x ULN
Alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) or ALT < 5.0 times ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ?2.5 times the upper limit of normal (ULN), or ?5 times the ULN for patients with liver metastases;
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 times ULN at the time of screening
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 times ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 times ULN or =< 5 times ULN if patient has documented liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases
Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 3.5 times ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN (=< 5.0 x ULN if due to leukemic involvement)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times ULN
Alanine aminotransferase (ALT) =< 3 times the ULN
alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN.
EXCLUSION CRITERIA FOR ENROLLMENT: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULN
EXCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 times above the ULN, ALT and AST can be < 5 times ULN if patients have hepatic involvement
Within 21 days prior to C1D1: Aspartate aminotransferase (AST) < 2.5 times ULN and alanine aminotransferase (ALT) < 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times ULN
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
Alanine aminotransferase (ALT) =< 2 times the ULN or aspartate aminotransferase (AST) =< 2 times the ULN; these values must be obtained within four weeks before protocol entry
Total bilirubin >1.5 times the upper limit of normal (ULN) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 X ULN at screening
Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT =< 2.5 times ULN is acceptable
Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) =< 2.5 times the ULN except in patients with hepatic metastases for whom AST and ALT must be < 5.0 times the ULN
Have serum aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) > 5 times ULN at screening, or total bilirubin >= 3.0 x ULN at screening (except for documented Gilbert's syndrome), by local or central lab. Subjects with biopsy confirmed CMV hepatitis will not be excluded from study participation despite AST or ALT > 5 times ULN at screening.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels >= 2.5 times the ULN or >= 5 times the ULN if liver metastases are present
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN in subjects without liver metastases or =< 5.0 times ULN in subjects with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Serum/plasma alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ?5 times ULN if there is liver or bone involvement.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 times the ULN if no liver metastases; for patients with known liver metastases, AST and ALT must be =< to 5 times the ULN
Serum/plasma alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ? 5 times ULN if there is liver or bone involvement.
Serum alanine aminotransferase < 3 times the upper limit of normal (ULN); Note: If elevated liver enzymes are related to disease alanine aminotransferase (ALT) should be < 5 times ULN
Hepatic: Bilirubin 1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) 3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?5.0 times ULN are acceptable. Alkaline phosphatase ?5.0 times ULN for participants with tumor involvement of the bone is acceptable.
Adequate hepatic function defined as: total bilirubin ?2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 times the institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 times the ULN, unless subjects have liver metastasis, in which case both AST and ALT must be less than or equal to 5 times the ULN
AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN
Alanine aminotransferase (ALT) < 2.5 times ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 times ULN
Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
Serum alanine aminotransferase or aspartate aminotransferase > 3 times ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN*
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN
Patient has poor liver function (> 2.5 times normal of alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) suggestive of cirrhosis or steatohepatitis
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN Note: If elevated liver enzymes, above the ULN, are related to disease; contact medical monitor to discuss.
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 times ULN for participants without liver metastases, or ?5 times ULN in the presence of liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times ULN for subjects without liver metastases, or ? 5 times ULN in the presence of liver metastases
Alanine aminotransferase and aspartate aminotransferase </= 3 times the ULN
Patients must have adequate hepatic function with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN within one week prior to treatment
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 times the ULN for the reference lab
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN
Subject has total serum bilirubin ?1.5 times the upper limit of normal (ULN),serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 3 times ULN, or albumin ? 3.0 g/dL at Screening.
Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </=2.5 times ULN (</=5 times ULN for subjects with liver involvement of their cancer)
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 1.5 times ULN at study entry
Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.5 times ULN
Adequate hepatic function within 21 days prior to randomization, with bilirubin < 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN.
Serum alanine aminotransferase < 2.5 times the ULN.
Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 5 times ULN
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note:If elevated liver enzymes are related to disease; contact medical monitor to discuss.
Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) >= 2.5 times the upper limits of normal (ULN) 14 days prior to study enrollment
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Liver function: total bilirubin ? 1.5 times the upper limit of normal (ULN) of each institution, aspartate aminotransferase and alanine aminotransferase ? 3 times the ULN range of each institution.
Hepatic: bilirubin ?1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) ?3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?5.0 times ULN are acceptable. Alkaline phosphatase ?5.0 times ULN for participants with tumor involvement of the bone is acceptable.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN (? 5 times ULN for patients with impaired liver function due primary tumor or metastatic disease)
Serum/plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ?5 times ULN if there is liver or bone involvement.